A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC

NCT06812260 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

SCLC, Extensive Stage

Interventions

DRUG: HLX10+chemo

Sponsor

Shanghai Henlius Biotech